Anti-GPC3 / Glypican-3 (Codrituzumab-MMAE) (D4061-GRP)

Anti-GPC3 / Glypican-3 (Codrituzumab-MMAE) is an antibody-drug conjugate (ADC) targeting GPC3 (glypican-3). It induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth and can be used in the research of hepatocellular carcinoma (HCC). MW :145.58 KD.